Radomska and colleagues (44) recently reported that FLT3 activation by its genetic mutation inhibits C/EBPα-induced myeloid differentiation through ERK1/2-mediated phosphorylation, and that FLT3 inhibitors can promote differentiation in leukemia cells with FLT3 mutations. Here, CEBPA is linked to leukemia.